2021 ASCO Annual Meeting coverage

News and expert insight from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

News highlight | Genitourinary cancers

KEYNOTE-564 supports adjuvant pembrolizumab use in high-risk RCC patients

News highlight | Breast cancer

‘Excellent’ outcomes with de-escalated neoadjuvant early breast cancer regimen

Video highlight | Lung and thoracic cancers

Patritumab deruxtecan shows promise for EGFR inhibitor-resistant NSCLC

More on breast cancer

18-06-2021 | ASCO 2021 | Conference coverage | Video

Clinical insights into breast cancer trials

Matteo Lambertini comments on the early and advanced breast cancer trials that caught his attention at the 2021 ASCO Annual Meeting, including the OlympiA, ECOG-ACRIN EA1131, GeparNUEVO, DAWNA-1, and sysucc-002 studies.

18-06-2021 | ASCO 2021 | Conference coverage | Video

Neoadjuvant talazoparib active in BRCA-mutated early breast cancer

Jennifer Litton discusses results of the NEOTALA trial suggesting patients with germline BRCA1/2-mutant, HER2-negative, early breast cancer may benefit from neoadjuvant treatment with talazoparib.

14-06-2021 | ASCO 2021 | Conference coverage | Video

Capecitabine remains the postoperative standard of care for TNBC with residual disease

Ingrid Mayer discusses findings from the ECOG-ACRIN EA1131 trial showing no benefit of postoperative platinum-based chemotherapy versus capecitabine in patients with triple-negative breast cancer who have residual disease following neoadjuvant chemotherapy.

10-06-2021 | ASCO 2021 | Conference coverage | Video

Perspectives on the OlympiA study of adjuvant olaparib in early breast cancer

08-06-2021 | ASCO 2021 | Conference coverage | Video

Three-weekly cabazitaxel not ruled out as first-line option for metastatic breast cancer

06-06-2021 | ASCO 2021 | Conference coverage | Video

OlympiA: Adjuvant olaparib delays recurrence of BRCA-mutant breast cancer

11-06-2021 | ASCO 2021 | Conference coverage | News

Patient survey points to need for innovative dosing strategies in MBC

10-06-2021 | ASCO 2021 | Conference coverage | News

Long-term benefits to neoadjuvant durvalumab in triple-negative breast cancer

08-06-2021 | ASCO 2021 | Conference coverage | News

‘Excellent’ outcomes with de-escalated neoadjuvant early breast cancer regimen

07-06-2021 | ASCO 2021 | Conference coverage | News

Lisinopril may prevent trastuzumab–anthracycline-related LVEF decline

07-06-2021 | ASCO 2021 | Conference coverage | News

Adding venetoclax to fulvestrant offers no extra benefit in VERONICA trial

06-06-2021 | ASCO 2021 | Conference coverage | News

DAWNA-1 brings new CDK4/6 inhibitor into HR-positive advanced breast cancer space

05-06-2021 | ASCO 2021 | Conference coverage | News

‘Meaningful benefit’ with adjuvant olaparib in BRCA-mutated early breast cancer

More on genitourinary cancers

18-06-2021 | ASCO 2021 | Conference coverage | Video

Additional insights from JAVELIN Bladder 100

Petros Grivas outlines the latest analyses of the JAVELIN Bladder 100 study of maintenance avelumab in metastatic urothelial cancer, including the assessment of efficacy by clinical and molecular subgroups and by the post-chemotherapy treatment-free interval, as well as data on time to end of subsequent therapy.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

17-06-2021 | ASCO 2021 | Conference coverage | Video

INDUCE-1 points to ICOS agonist activity in advanced urothelial cancer

Arjun Balar talks through the INDUCE-1 trial findings for patients with advanced urothelial carcinoma who were given the ICOS agonist feladilimab alone or alongside pembrolizuamb.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

14-06-2021 | ASCO 2021 | Conference coverage | Video

Pembrolizumab benefit confirmed for cisplatin-ineligible advanced UC patients

Peter O’Donnell gives an update on the KEYNOTE-052 trial findings for first-line pembrolizumab in cisplatin-ineligible patients with advanced urothelial carcinoma.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

11-06-2021 | ASCO 2021 | Conference coverage | Video